Breaking News

Biden's planned CDC director pick, Ozempic adherence, & surgeons balking at top surgery for fat patients

June 2, 2023
Reporter, Morning Rounds Writer
Good morning. We have news on the likely candidate to lead the CDC after Rochelle Walensky departs later this month, a look at how long people stay on Ozempic (and at what cost), and a look ahead to the major cancer conference ASCO.

CDC

Biden set to pick North Carolina physician to lead CDC

President Biden is planning to nominate Mandy Cohen, a physician and former North Carolina health secretary, to lead the CDC, the Washington Post reported yesterday. Cohen will succeed Rochelle Walensky when she leaves the embattled health agency on June 30. Cohen is now the CEO of health care company Aledade Care Solutions, which supports primary care practices in accountable care organizations.

Walensky's tenure was marked by criticism of the agency's Covid-19 response. She was the architect of a plan to speed CDC's release of scientific research and improve communication of health messaging, but will have departed before it takes effect. Cohen was previously in the running to lead CMS, STAT reported in 2021, and she was also approached for the CDC post before Walensky had announced her departure, the Post said.


chronic disease

Insurance wasn't enough to keep patients on Ozempic

While next-generation weight loss drugs are in high demand, a new study takes a look at how long people stay on the medications approved for diabetes but linked to dramatic weight loss — once they obtain them. Even if people have health insurance coverage, high copays can deter them from staying on the drugs, researchers report in JAMA Network Open. Insured patients with type 2 diabetes and heart failure who face copays of $50 or more were 50% less likely to keep taking Ozempic and Trulicity than people whose copays were $10 or less.

The findings were based on 94,000 people from 2014 to 2020 — before Wegovy, a drug similar to Ozempic that treats obesity, was approved. For the older drugs Jardiance and Farxiga, the high vs. low copayment gap was about 30%. Medicare doesn't cover weight loss drugs and private insurance coverage is spotty. STAT's Elaine Chen has more.


cancer

What we're watching at ASCO

With the American Society of Clinical Oncology annual meeting kicking off today, STAT cancer reporter Angus Chen has a sneak peek of just a few of the clinical trial results he'll be watching for. Sign up for STAT's pop-up ASCO in 30 newsletter, which will send tomorrow through Monday, here

  • AstraZeneca's osimertinib (Tagrisso) for lung cancer: Clinicians have long debated whether AstraZeneca's EGFR targeted drug osimertinib was a worthwhile treatment for lung cancer patients, given that there was no data on the drug's effect on overall survival rates. Now AstraZeneca will release the full results of a Phase 3 trial that found the drug had a "significant" survival benefit.
  • Servier's vorasidenib for low-grade glioma: Servier's Phase 3 trial results will have data showing its IDH1 and IDH2 inhibitor vorasidenib met the primary endpoint of progression-free survival in low-grade glioma. This could be a big deal for a setting that hasn't seen major advancements in treatment in decades.
  • Novocure's TTF therapy for non-small cell lung cancer: Novocure will present Phase 3 results on TTF therapy for metastatic, non-small cell lung cancer. Tumor treating fields, or TTF, are electrical fields generated by a worn device that are supposed to help fight cancer. But Novocure's device, Optune, has a hefty price tag, costing hundreds of dollars per day.


Closer Look

Studies say top surgery is safe for fat people, but some surgeons still balk

Vince Wescott poses for a portrait in his home.Logan Cyrus for STAT

Transmasculine people who decide to have top surgery face hurdles. They need to secure insurance approval, find thousands of dollars to cover fees, take time off work, and in some cases, supply a letter from a therapist. But their body size could still keep them from the gender-affirming procedure. "The doctor had a look at the pictures and your weight is very concerning," Vince Wescott (above) recalled a nurse saying. "He is not going to be able to do this unless you lose about 100 pounds." 

That common experience flies in the face of research showing that top surgery is safe. The complication rates for patients with higher BMIs aren't much higher than for those with lower BMIs, in contrast to facial feminization, breast augmentation, and genital (bottom) surgeries. STAT contributor H Conley explains how anti-fat bias is often compounded by transphobia and racism, leading to worse health outcomes. Read more.


medicare

Medicare holds steady on coverage for new Alzheimer's drugs

It's not just Aduhelm. After the FDA granted accelerated approval to that  polarizing Alzheimer's drug in 2021, Medicare restricted coverage for all Alzheimer's drugs in that class, requiring patients to be enrolled in clinical trials. Now, despite pressure from Congress and advocates, Medicare is sticking with that plan. Its Thursday statement repeated the agency's mandate to monitor patients to see how well the treatments work, even beyond full FDA approval.

That could prove significant for Eisai's Leqembi, which might gain full approval within the next month. If it does, those restrictions will relax slightly, but providers would still need to collect data about all patients who receive the drugs in a patient registry. Leqembi's effectiveness data are promising, but brain swelling and potential connections to the deaths of three patients in clinical trials have caused alarm. STAT's Rachel Cohrs explains.


Public health

Cherokee Nation reports progress and gaps in eliminating hepatitis C infections

Screen Shot 2023-06-01 at 2.30.35 PMCDC

Because American Indian and Alaska Native people are disproportionately affected by hepatitis C virus infections, Cherokee Nation Health Services  — which provides care for more than 100,000 people in 11 health care facilities across the reservation — launched a program in 2015 to eliminate the curable disease. After five years, 1,423 people were diagnosed with hepatitis C infections. While 86% of them were connected to care, only 56% completed treatment and 49% were declared free of the virus at 12 weeks after concluding treatment.

Reasons for the gap between diagnosis and treatment may have to do with payment, the CDC report suggests. Medicaid didn't cover treatment for people with little or no liver scarring until 2018 and payers required prior authorization and sometimes a specialist visit before approving medications. "Barriers to [hepatitis C] treatment initiation need to be addressed to achieve [hepatitis C] elimination," the researchers write.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • A catatonic woman awakened after 20 years. Her story may change psychiatry, Washington Post
  • An inside look at Covid's lasting damage to the lungs, New York Times
  • Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts, STAT

  • Black men were likely underdiagnosed with lung problems because of bias in software, study suggests, Associated Press

  • Tempus launches an AI 'assistant' for thousands of oncologists, STAT


Thanks for reading! More Monday,


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments